Business Wire

CA-ANDERSEN-GLOBAL

20.9.2019 11:50:05 CEST | Business Wire | Pressemeddelelse

Del
Andersen Global udvider rækkevidde i London

Andersen Global fortsætter sin udvidelse i Storbritannien, idet Miles Dean, Zoe Wyatt og deres team slutter sig til Andersen Tax LLP-teamet i Storbritannien. Denne tilføjelse giver yderligere dybde til koncernen i London og forbedrer teamets evne til at arbejde sammen med kunder på en helhedsorienteret måde og yde uovertruffen og effektiv service. Andersen Global er repræsenteret fem steder i Storbritannien igennem sine medlems- og samarbejdsfirmaer.

Miles og Zoe har tidligere arbejdet for Milestone, som blev grundlagt af Miles Dean i 2008, og Zoe Wyatt blev partner i 2015. Som en del af Andersen Tax LLP vil disse partnere fortsat levere en bred vifte af internationale skattetjenester til virksomheder og private kunder, investeringsfonde og ejendomsinvestorer og -udviklere. Milestone underskrev en samarbejdsaftale med Andersen Global i 2018, og den positive indvirkning af dette forhold har ført til, at Miles, Zoe og deres team nu slutter sig til Andersen Global-medlemsfirmaet i Storbritannien.

“Det var enormt vigtigt for os at sikre, at vi er i stand til at yde det bedste for vores kunder. Vi ser virkelig frem til at fortsætte med at levere effektiv service og fordelen ved ekspertise fra de bedste rundt omkring i verden som en del af Andersen Global-familien,” sagde Miles Dean, grundlæggende partner hos Milestone og nu partner hos Andersen Tax LLP. “Jeg sætter pris på ​​at samarbejde med ligesindede partnere over hele kloden, og vores tid med Andersen Global, både som et samarbejdsfirma og nu som en del af det britiske medlemsfirma, har vist en fælles forpligtelse til at levere service af høj kvalitet.”

“At have Miles og Zoe som partnere i vores team er en naturlig udvikling, da vi har arbejdet tæt sammen med dem i mere end to år. Som en del af Andersen Tax LLP vil teamets komplementære ekspertise og erfaring give vores bredere koncern et markant løft på det dynamiske britiske marked, idet vi udvider vores rækkevidde i hele landet og globalt,” sagde George McCracken, administrerende direktør for Andersen Tax LLP.

“Miles, Zoe og deres team giver den slags unikke ekspertise og dedikation, der uden tvivl skiller sig ud fra resten. Teamet er indbegrebet af de egenskaber, som vi værdsætter hos Andersen, såsom gennemsigtighed, uovertruffen service og ledelse,” sagde Mark Vorsatz, bestyrelsesformand for Andersen Global og administrerende direktør for Andersen. “Idet vi fortsætter med at tilføje og udvide vores evner for kunder i Storbritannien, bygger vi videre på det eksisterende fundament i regionen og viser vores ildhu for at tilbyde effektive services over hele kloden.”

Andersen Global er en international sammenslutning af juridisk separate, uafhængige medlemsfirmaer, der består af skatte- og juraeksperter fra hele verden. Andersen Global blev etableret af det amerikanske medlemsfirma Andersen Tax LLC i 2013 og har nu over 4.500 eksperter verden over og er repræsenteret mere end 149 steder igennem medlems- og samarbejdsfirmaer.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye